DefenCath® (taurolidine and heparin) catheter lock solution is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.

Press releases

Here you can find corporate releases on topics related to governance, investments, and important announcements.

Read more

Investors

Nasdaq:

CRMD

$ 3.3 Last update: 02/22/2024 4:01:20 pm ET Time Read more

About CRBSI

Learn more about Catheter-related blood stream infections (CRBSIs) and how they affect hemodialysis central venous catheter (HD-CVC) patients.

Read more
WHY CORMEDIX

We relentlessly pursue therapeutic options to reduce and treat infectious and inflammatory disease

About us